



Loïc Kubitza  
Director

PricewaterhouseCoopers  
400, route d'Esch  
L-1014 Luxembourg

+352 49 48 48 4180  
loic.x.kubitza@lu.pwc.com

Loïc Kubitza is the director responsible for deal advisory services to the life sciences sector at PwC in Luxembourg.

He has focused on deal and strategy advisory work in the pharmaceuticals and life sciences sector since 1995 at PwC in London. In 2003, Loïc went on a career break to complete an MSc in Molecular Medicine and work on a cancer research project at The Medical Research Council, Hammersmith Hospital, London. His research focused on finding novel genes involved in the development of drug resistance.

Loïc moved to Luxembourg in November 2008 following the country's increasing diversification into life sciences. At PwC in Luxembourg, he has worked with companies in the diagnostics and pharmaceutical sectors including fund raising, licensing and strategy advisory mandates. He was the main co-author of the PwC study *Diagnostics 2009: Moving towards personalised medicine*.

Personalised medicine became an important focus area for PwC in Luxembourg as the government announced plans to invest €140 million into three research projects involving leading US based scientists: Jeffrey Trent (Translational Genomics Research Institute), Leland Hartwell (Nobel Prize 2001 and Partnership for Personalised Medicine) and Leroy Hood (Institute for Systems Biology).

Clients included: GlaxoSmithKline, AstraZeneca, MerckSerono, Q-One Biotech, The Medical Research Council, Berna Biotech, Pharmion, Mundipharma, Galenica, Actavis, NextPharma and financial investors.

Loïc has an MSc in Molecular Medicine (Imperial College), an MSc in Economics (Université Catholique de Louvain) and is a Chartered Accountant (ICAEW). He passed the APBI's Medical Representative exam.